Why Amgen Is Up Despite Falling Product Sales

Health and Healthcare

Published: July 31, 2019 10:00 am

Last Updated: January 30, 2020 5:53 pm

When Amgen Inc. (NASDAQ: AMGN) released its second-quarter financial results after the markets closed on Tuesday, the firm said that it had $3.97 in earnings per share (EPS) and $5.9 billion in revenue. That compared with consensus estimates of $3.58 in EPS and $5.66 billion in revenue, as well as the $3.83 per share on $6.06 billion posted in the same period from last year.

During the most recent quarter, revenues decreased 3% year over year, reflecting increasing competition due to patent expirations. Product sales fell 2% in the time as well.

In terms of its product sales, Amgen reported as follows:

Prolia, $698 million
Evenity, $28 million
Repatha, $152 million
Aimovig, $83 million
Parsabiv, $168 million
Kyprolis, $267 million
Xgeva, $499 million
Vectibix, $196 million
Nplate, $201 million
Blincyto, $78 million
Enbrel, $1.36 billion
Neulasta, $824 million
Neupogen, $75 million
Epogen, $223 million
Aranesp, $436 million
Sensipar/Mimpara, $122 million

Looking ahead to the full year, the company expects to see EPS in the range of $13.75 to $14.30 and revenue between $22.4 billion and $22.9 billion. Consensus estimates are calling for $13.97 in EPS and $22.59 billion in revenue for the year.

Apart from this, Amgen said that its experimental cancer drug AMG510 demonstrated activity in patients with colorectal and appendiceal cancer. Previously, the firm presented data in June suggesting AMG510 appeared to be effective against lung cancer. Amgen expects to begin a trial later this year that could serve as the basis for a U.S. regulatory application seeking approval.

Robert A. Bradway, board chair and chief executive, commented:

With our newer products generating strong volume gains globally and many first-in-class medicines advancing through our pipeline, we are well positioned to serve patients and deliver long-term growth for our shareholders.

Shares of Amgen closed Tuesday at $176.45 but traded early Wednesday at $181.88. The 52-week range is $166.30 to $210.19, and the consensus price target is $204.43.

ALSO READ: These Older, Common Drugs Could Help Fight Cancer, New Study Says

In 20 Years, I Haven’t Seen A Cash Back Card This Good

Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. Our top pick today has pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.